Nanollose Limited (ASX:NC6) is pleased to announce that it has obtained favourable findings from the Department of Industry, Innovation and Science which will enable the Company to claim tax rebates on certain overseas research and development expenditure up to $1.419 million over the next three years.
The Board of Queensland Bauxite Limited (ASX:QBL) is very pleased to announce a materially strategic transaction, that its soon to be wholly owned subsidiary Medcan Australia, has entered into a Strategic Collaboration and Supply Agreement Signed with an established Canadian Licensed Producer of Medical Cannabis.
Regeneus Ltd (ASX:RGS) provides the Company's quarterly results for the period ended 30 September 2018.
Anatara Lifesciences (ASX:ANR), a company focused on commercialising innovative products for gut health, is pleased to announce the formation of its Product Development Advisory Board. The Advisory Board consists of five key external experts: Dr Rebecca Burgell, Dr Jakob Begun, Prof Barry Campbell, Assoc Prof Simon Keely and Prof Peter Gibson, who will serve as the Chairman.
Queensland Bauxite Ltd (ASX:QBL) provides the Company's Annual Report to shareholders.
The Board of Queensland Bauxite Limited (ASX:QBL) is very pleased to announce a materially strategic transaction, that its soon to be wholly owned subsidiary Medcan Australia, has entered into a memorandum of understanding with top Israeli medicinal cannabis company Pharmocann.
Oventus Medical Ltd (ASX:OVN) is pleased to announce that new clinical data from four separate studies on its Sleep Treatment Platform will be presented at Sleep DownUnder, the 30th annual meeting of sleep specialists, taking place in Brisbane between 17th -20th October.
